• Product NameAvitinib maleate
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityAfatinib?is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
• Target NameEGFR inhibitor
• CAS No. 1557268-88-8
• Calculated MW 603.61
• Formulation C30H30FN7O6
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=CN4)C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)F.C(=C\C(=O)O)\C(=O)O
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Xu X. Parallel phase 1 clinical trials in the US and in Chinaet al.Chin J Cancer. 2015 Jul 8;34(7):285-7.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting